Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Hisamatsu, Takeshi; McGuire, Michael; Wu, Sherry Y.; Rupaimoole, Rajesha; Pradeep, Sunila; Bayraktar, Emine; Noh, Kyunghee; Hu, Wei; Hansen, Jean M.; Lyons, Yasmin; Gharpure, Kshipra M.; Nagaraja, Archana S.; Mangala, Lingegowda S.; Mitamura, Takashi; Rodriguez-Aguayo, Cristian; Eun, Young Gyu; Rose, Johnathon; Bartholomeusz, Geoffrey; Ivan, Cristina; Lee, Ju-Seog; Matsuo, Koji; Frumovitz, Michael; Wong, Kwong K.; Lopez-Berestein, Gabriel; Sood, Anil K.

doi:10.1158/1535-7163.22504399.v1

15357163mct171050-sup-191519_2_supp_4938291_pcv5hr.docx (2 MB)

Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

journal contribution

posted on 2023-04-03, 15:00 authored by Takeshi Hisamatsu, Michael McGuire, Sherry Y. Wu, Rajesha Rupaimoole, Sunila Pradeep, Emine Bayraktar, Kyunghee Noh, Wei Hu, Jean M. Hansen, Yasmin Lyons, Kshipra M. Gharpure, Archana S. Nagaraja, Lingegowda S. Mangala, Takashi Mitamura, Cristian Rodriguez-Aguayo, Young Gyu Eun, Johnathon Rose, Geoffrey Bartholomeusz, Cristina Ivan, Ju-Seog Lee, Koji Matsuo, Michael Frumovitz, Kwong K. Wong, Gabriel Lopez-Berestein, Anil K. Sood

Figure S1 shows results od cell viability assays, PRKRA expressions and time course experiments. Figure S2 shows results of heatmap for gene expressions and IPA. Figure S3 shows results of cell viability assay, in vivo experiment. Figure S4 shows the results of experiments for PACT-Dicer or PACT- miR 515-3p interaction. Figure S5 shows the results of experiments for miR-515-3p-AXL interaction.

Funding

Uehara Memorial Foundation

CPRIT

NIH

Cancer Prevention Research Institute of Texas

History

ARTICLE ABSTRACT

For mucinous ovarian cancer (MOC), standard platinum-based therapy is largely ineffective. We sought to identify possible mechanisms of oxaliplatin resistance of MOC and develop strategies to overcome this resistance. A kinome-based siRNA library screen was carried out using human MOC cells to identify novel targets to enhance the efficacy of chemotherapy. In vitro and in vivo validations of antitumor effects were performed using mouse MOC models. Specifically, the role of PRKRA/PACT in oxaliplatin resistance was interrogated. We focused on PRKRA, a known activator of PKR kinase, and its encoded protein PACT because it was one of the five most significantly downregulated genes in the siRNA screen. In orthotopic mouse models of MOC, we observed a significant antitumor effect of PRKRA siRNA plus oxaliplatin. In addition, expression of miR-515-3p was regulated by PACT–Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin. Mechanistically, miR-515-3p regulated chemosensitivity, in part, by targeting AXL. The PRKRA/PACT axis represents an important therapeutic target in MOC to enhance sensitivity to oxaliplatin.

Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Funding

Uehara Memorial Foundation

CPRIT

NIH

Cancer Prevention Research Institute of Texas

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports